ONCOLOGY Vol 25 No 12 | Oncology

Perspectives on the New PSA Screening Recommendations

November 21, 2011

This is a very emotional issue. Any time a group claims less screening is good, I always take it with a grain of salt-yet the data certainly seem to support that generalized screening with PSA may not impact survival in the general population.

Hepatic Metastasectomy for Breast Cancer and Melanoma: Trends in Highly Selected Patients

November 15, 2011

Hepatic metastases remain a lethal and recalcitrant problem in the management of malignant disease, and the review by Drs. Zani and Clary of the role of hepatic metastasectomy for patients with stage IV melanoma or breast cancer is timely and welcome.

Thoracic Metastases From Sarcoma: a Commentary

November 15, 2011

Surgical resection of isolated pulmonary metastases has been incorporated into the management of cancer for more than 70 years. However, many questions still remain concerning indications, technique, and efficacy for this approach.

Innate Immune B Cells Gone Bad

November 15, 2011

Normal B lymphocytes can follow either of two functionally distinct pathways of development. The first is a classical germinal center T-dependent pathway in which diversification and maturation generate a delayed but almost unlimited high-affinity response to antigens.

It Is Better to Do RIC Without ATG

October 24, 2011

ATG is associated with reduced risk of acute and chronic graft-versus-host disease without increasing the risk of relapse in myeloablative donor transplants. However, there has been an ongoing debate about the role of ATG in reduced intensity conditioning (RIC) HSCT, and there are still bone marrow transplant centers that use ATG in the RIC setting, and their main argument is that ATG could help with engraftment and reducing the risk of GVHD. Different types and doses of ATG have been used in the RIC setting.

Long-Term Study Finds Vitamin E Supplements Raise the Risk of Prostate Cancer

October 13, 2011

Vitamin E supplements, rather than reducing the risk of prostate cancer have been found to increase the risk of developing the disease. The findings are a 3-year follow-up to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Growing Number of Cancer Survivors Among Aging Population as Baby Boomers Pass the 65-Year Mark

October 06, 2011

A recent epidemiology study by the NCI has found an almost four-fold increase of cancer survivors since 1971: 11.9 million in 2008 compared with 3 million in 1971, and the authors of the study expect a 42% increase in the number of older adult survivors in the next 10 years.

Erlotinib as Maintenance Therapy Shows PFS Benefit for Lung Cancer Patients with EGFR-Mutated Tumors

October 05, 2011

of a prospective biomarker analysis for the phase III SATURN trial in NSCLC patients taking erlotinib as maintenance therapy now show that those with activating EGFR mutations had extended progression-free survival compared to patients with KRAS mutations.

EMCC: Phase III Aflibercept-Chemotherapy Combination Trial Shows Benefit in Previously Treated Metastatic Colorectal Cancer Patients

September 30, 2011

Dr. Josep Tabernero of the Vall D'Hebron University Hospital in Barcelona presented the positive results of the VELOUR study on Sunday September 25, including the newly presented pre-specified subgroup analysis. The primary endpoint results had been reported at the ESMO/WCGC meeting earlier this year.

EMCC: Oral Anti-Angiogenesis Treatment Plus Chemotherapy Is Not More Efficacious Than Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer

September 30, 2011

This phase I/II trial assessed the efficacy of mFOLFOX6 with either BIBF 1120, an oral anti-angiogenesis agent, or with bevacizumab, an anti-angiogenesis antibody, in chemotherapy-naïve patients with metastatic colorectal cancer (mCRC). Patients were randomized 2:1 to the BIBF 1120 and bevacizumab arms, respectively.

EMCC: Radium-223 Plus Chemo Shows Clear OS Benefit

September 29, 2011

Radium-223, an alpha particle given intravenously, has been shown to improve overall survival in men with castrate-resistant prostate cancer (CRPC), with a 30% risk reduction of death (HR = 0.695, P = 0.00185).

EMCC: AZURE Subgroup Analysis Shows Adjuvant Therapy With Zoledronic Acid May Benefit Breast Cancer Patients Postmenopausal > 5 Years

September 29, 2011

Results of the AZURE trial revealed small improvements in disease-free and overall survival when zoledronic acid was used in addition to adjuvant therapy in a subgroup of early-stage breast cancer patients who had been postmenopausal for more than 5 years.

EMCC: Speakers Look Forward To Widespread Personalized Patient Care

September 28, 2011

The European Multidisciplinary Cancer Congress, taking place from September 23rd to the 27th in Stockholm, brings together the European oncology community and is a joint effort between the European Society for Medical Oncology (ESMO), the European Cancer Organization (ECCO) and the European Society for Therapeutic Radiology and Oncology (ESTRO).